TransCode Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 536.81% HC Wainwright & Co. → $3 Reiterates Buy → Buy 04/03/2024 536.81% HC Wainwright & Co. →
BenzingaApr 16 10:49 ET
TransCode Therapeutics: A Promising Oncology Investment With FDA-Backed Clinical Advancements
TipRanksApr 15 12:35 ET
Express News | Transcode Therapeutics Announces FDA Clearance to Initiate Phase 1/2 Clinical Trial With Ttx-Mc138 in Patients With Advanced Solid Tumors
Moomoo 24/7Apr 15 09:00 ET
Promising Phase 0 Results and Upcoming Trial Boost Confidence in TransCode Therapeutics
TipRanksApr 3 12:05 ET
Express News | HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target
Moomoo 24/7Apr 3 12:03 ET
TransCode Therapeutics Reports FY Results
Seeking AlphaApr 3 10:29 ET
TransCode Therapeutics Appoints Vlock as Chief Medical Officer
Seeking AlphaMar 28 09:01 ET
Express News | TransCode Therapeutics and Akribion Genomics Report Proof-Of-Concept Laboratory Studies In Human Cells; Say Studies To Date 'Suggest That Akribion's G-dase E Ribonucleoprotein Complexes Could Be Conjugated to TransCode's TTX Delivery Platform, Suggesting
Moomoo 24/7Mar 11 09:01 ET
Express News | TransCode Therapeutics Reports Publication Of U.S. Patent Application Titled, "Nanoparticles And Template Directed RIG-I Agonist Precursor Compositions And Uses Thereof For Cancer Therapy"
Moomoo 24/7Feb 20 08:08 ET
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic
BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported publication of United
GlobeNewswireFeb 20 08:00 ET
Express News | Transcode Therapeutics Filed U.S. Patent Application # 20240042070: NANOPARTICLES AND TEMPLATE DIRECTED RIG-I AGONIST PRECURSOR COMPOSITIONS AND USES THEREOF FOR CANCER THERAPY
Moomoo 24/7Feb 8 16:03 ET
Express News | TransCode Therapeutics Regained Compliance With Nasdaq
Moomoo 24/7Jan 31 16:55 ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersTransCode Therapeutics (NASDAQ:RNAZ) shares moved upwards by 17.2% to $0.81 during Wednesday's after-market session. Align Tech (NASDAQ:ALGN) shares increased by 13.29% to $302.86. The company'
BenzingaJan 31 16:31 ET
Transcode Therapeutics Regains Compliance With Nasdaq Listing Rules
Seeking AlphaJan 31 16:14 ET
TransCode Therapeutics, Debiopharm Collaborate to Develop Nucleic Acid Therapies for Cancer
TransCode Therapeutics (RNAZ) said Monday said it entered into a co-research agreement with Swiss-based biopharmaceutical company Debiopharm to develop targeted nucleic acid therapeutics for cancer.
MT NewswiresJan 29 13:40 ET
Looking Into TransCode Therapeutics's Recent Short Interest
TransCode Therapeutics's (NYSE:RNAZ) short percent of float has risen 2201.23% since its last report. The company recently reported that it has 394 thousand shares sold short, which is 37.51% of all r
BenzingaJan 29 13:30 ET
Express News | TransCode Therapeutics Collaborates With Debiopharm; Financial Terms Not Disclosed
Moomoo 24/7Jan 29 08:40 ET
Press Release: TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the "Company"), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced public offering of an aggregate of 5,942,623 shares of its common stock (or common stock equivalents) and warrants to purchase up to 11,885,246 shares of common stock at a combined public offering price of $1.22 per share (or per common stock equivalent) and accompanying warrants.
Dow JonesJan 22 16:45 ET
12 Health Care Stocks Moving In Monday's After-Market Session
GainersCadrenal Therapeutics (NASDAQ:CVKD) shares moved upwards by 8.5% to $1.15 during Monday's after-market session. The market value of their outstanding shares is at $14.9 million. vTv Therapeutic
BenzingaJan 22 16:31 ET
CRGE and LAES Among Mid-day Movers
Seeking AlphaJan 19 12:42 ET
No Data
No Data